SVB Leerink Maintains Outperform on Relmada Therapeutics, Lowers Price Target to $10
SVB Leerink analyst Marc Goodman maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and lowers the price target from $42 to $10.
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In Q1 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ:VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday’s regular session. Trading volume for…
Looking Into Relmada Therapeutics’s Recent Short Interest
Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 8.99% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 9.31% of all regular shares that are available for trading.
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday.
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday’s Mid-Day Session
Gainers
My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 138 companies set new 52-week lows.
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday.
Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke
Relmada Therapeutics Inc (NASDAQ:RLMD) announced the results of the RELIANCE I REL-1017-301 study evaluating REL-1017 as an adjunctive treatment…